Stay updated with breaking news from Douglasl Mann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A new study led by researchers at Washington University School of Medicine in St. Louis suggests that a widely used heart failure drug named sacubitril/valsartan is no better than valsartan alone in patients with severe heart failure.
A new study led by researchers at Washington University School of Medicine in St. Louis suggests that a widely used heart failure drug named
Patients with heart failure with reduced ejection fraction (HFrEF) did not have better health outcomes if they took sacubitril/valsartan combination therapy compared with valsartan alone, according to new data presented at the American College of Cardiology's 70th Annual Scientific Session.